What RiskReveal is
A digital ethnography and scientific-literature synthesis. Two streams of evidence. One curated, decision-ready read.
RiskReveal is not a raw data dump and not generic social listening. It is synthesis with pharma context, written for decision use — by a patient expert and a merakoi strategist who interpret what the AI surfaces.
How it works
Two parallel streams feed a single curated synthesis.
Scientific literature scan
A structured review of clinical and observational evidence on benefit-risk, treatment choice, and disease management for the population in scope.
Digital ethnography
Listening across the public record — forums, social, patient communities, published patient narratives — for the lived experience of benefit-risk and treatment choice.
When to use RiskReveal
- You're targeting a population that is hard to engage primarily — adolescents, young adults, stigmatised conditions, populations unfamiliar with the pharma industry
- You want a grounded benefit-risk foundation before fielding primary research
- You're asking benefit-risk questions broader than safety alone — preference, treatment choice, lifecycle moments
- You need a credible synthesis for an internal scientific or commercial audience
Engagement modes
RiskReveal is offered as a component of a Lab engagement, or as a standalone lead-in where a Lab is the expected next step. It is not sold as a one-off deliverable with no downstream Lab.
Language coverage: global English by default for both literature and digital-ethnography streams. Multi-language coverage available where feasibility allows.
Why choose RiskReveal
Human-curated, not auto-generated
A patient expert and a merakoi strategist read and interpret what the AI surfaces. Synthesis is the deliverable, not the data.
Built for hard-to-reach populations
When primary engagement is constrained — adolescents, young adults, stigmatised conditions — RiskReveal is the right input layer.
Benefit-risk, not just safety
The methodology covers the full benefit-risk territory, including preference and treatment choice, not safety in isolation.
Book a Consultation to scope your RiskReveal.
A short call to frame the population, the decision, and whether RiskReveal fits as a Lab component or a lead-in.
